logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Jiufang Zhitou Holdings (09636.HK) repurchased 95,900 shares on November 6 for HK$2.3275 million.

date
06/11/2026
Zhitong Finance APP News, Jiufang Zhitou Holdings (09636.HK) announced that on November 6, 2026, the company spent HK$2.3275 million to repurchase 95,900 shares at a repurchase price of HK$23.96-24.38 per share.
Latest
now
Xiang Jun increases shareholding in Kong Sun Holdings (00295.HK) by 73.35 million shares at HK$0.013 per share
1 m ago
North China Pharmaceutical (600812.SH): Marketing application for cefradine API approved
1 m ago
HKEX shareholders approve new articles of association, paving the way for the implementation of an uncertificated securities regime.
1 m ago
Wang Huan increased his holdings in Global New Material International (06616.HK) by 110,000 shares at approximately HK$8 per share.
2 m ago
Moderna raised its full-year guidance and reported its first quarterly profit since 2024, mainly driven by a sharp rebound in COVID-19 vaccine sales from a year earlier. The company said Friday it expects revenue to grow 15% to 25% this year, up from its previous forecast of 10%. Third-quarter profit also beat the average estimate of Wall Street analysts compiled by FactSet, who had expected a loss. Moderna, known for its COVID-19 vaccine, is trying to open up new sources of growth by shifting its focus toward cancer drug development. The mRNA skin cancer vaccine it is developing with Merck recently succeeded in a late-stage clinical trial, pushing its shares to multi-year highs. As of Thursday, the stock had risen more than 700% year to date. If approved, the drug would mark a major breakthrough for Moderna's core technology. Moderna expects the drug, called intismeran, to potentially win U.S. approval next year.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.